Student Political Engagement in the Co-Curriculum: Understanding the Role of Senior Student Affairs Officers

The apolitical nature of the civic engagement movement poses challenges to our democracy (Saltmarsh & Hartley, 2011). The co-curricular experience is well positioned to address this phenomenon but little research exists to inform practice. This qualitative study uncovers how the socialization of senior student affairs officers (SSAO) influences approaches to student civic/political development. Implications for practice and future research are presented based on the findings from the study

“Are We Really Not Going to Talk about the Black Girl?”: The Intergroup Racial Attitudes of Senior, White, Sorority Women

Despite the positive effects of cross-racial interactions for students, predominantly White sororities remain segregated. Utilizing focus group methods, this study investigates the racial attitudes of White sorority women to understand the influence of sororities on racial attitudes. Findings revealed that participants in this study minimized race, thought about diversity within context, and perceived barriers to cross-racial interactions. These findings have important implications for campus professionals who work with sorority women

Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)

Purpose: Jain Sorafenib is a multi-targeted tyrosine kinase inhibitor with therapeutic efficacy in several malignancies. Sorafenib may exert its anti-neoplastic effect in part by altering vascular permeability and reducing intra-tumoral interstitial hypertension. As correlative science with a phase II study in patients with advanced soft-tissue sarcomas (STS), we evaluated the impact of this agent on intra-tumor interstitial fluid pressure (IFP), serum circulating biomarkers, and vascular density. Patients and Methods: Patients with advanced STS with measurable disease and at least one superficial lesion amenable to biopsy received sorafenib 400 mg twice daily. Intratumoral IFP and plasma and circulating cell biomarkers were measured before and after 1–2 months of sorafenib administration. Results were analyzed in the context of the primary clinical endpoint of time-to-progression (TTP). Results: In 15 patients accrued, the median TTP was 45 days (range 14–228). Intra-tumoral IFP measurements obtained in 6 patients at baseline showed a direct correlation with tumor size. Two patients with stable disease at two months had post-sorafenib IFP evaluations and demonstrated a decline in IFP and vascular density. Sorafenib significantly increased plasma VEGF, PlGF, and SDF1$\alpha$ and decreased sVEGFR-2 levels. Increased plasma SDF1$\alpha$ and decreased sVEGFR-2 levels on day 28 correlated with disease progression. Conclusions: Pretreatment intra-tumoral IFP correlated with tumor size and decreased in two evaluable patients with SD on sorafenib. Sorafenib also induced changes in circulating biomarkers consistent with expected VEGF pathway blockade, despite the lack of more striking clinical activity in this small series